SALT LAKE CITY, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ending December 31, 2010. Revenue for the second fiscal quarter was $100.4 million, an increase of 8 percent over the $92.8 million reported in the second fiscal quarter of 2010. Operating income was $38.6 million, an increase of 12 percent from the prior-year period.